Company intelligence / Profile preview
DIOSynVax
Cambridge, England, United Kingdomdiosynvax.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
DIOSynVax has demonstrated safety in a "First-in-Human" Phase I trial of its digitally engineered coronavirus vaccine. Its bird flu/universal influenza candidate has shown efficacy and safety in animal models and is ready to enter human trials. The company’s approach leverages AI-driven computational biology to design broad-spectrum synthetic antigens that elicit robust immune responses against highly variable pathogens.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Synthetic vaccine antigens (digitally engineered)mRNA (in partnership programs)Multivalent vaccine antigen payloads (VAPs)
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
ProBioGen AG (manufacturing partner for hemorrhagic fever vaccine candidate)Ethris GmbH (mRNA delivery technology collaboration)University of Cambridge spinout/collaboration origin
Beyond the preview
Go deeper on DIOSynVax.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DIOSynVax.